SetPoint Medical is dedicated to treating patients with debilitating inflammatory diseases, such as Crohn's Disease and rheumatoid arthritis, using proprietary implantable neuromodulation devices.
The scientific platform is based on the Inflammatory Reflex—the natural mechanism by which the central nervous system regulates the immune system. This mechanism was discovered by SetPoint co-founder Kevin Tracey and published in Nature in May 2000. Since then, the Inflammatory Reflex has been characterized in more than 100 peer reviewed papers in leading scientific journals. Anti-inflammatory potency comparable to leading drugs has been demonstrated in multiple animal models. The company is currently conducting human trials in rheumatoid arthritis at four European centers.
SetPoint's microregulator is intended to supplement the body's natural Inflammatory Reflex by providing 'built-in' therapy at a lower cost and with improved safety compared with drugs or biologic solutions.